Eric J Lavonas1, Vaishali Khatri2, Claire Daugherty3, Becki Bucher-Bartelson2, Thomas King3, Richard C Dart4. 1. Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, Denver, CO; Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO. Electronic address: eric.lavonas@rmpdc.org. 2. Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, Denver, CO. 3. BTG International, Inc., West Conshohocken, PA. 4. Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, Denver, CO; Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO.
Abstract
STUDY OBJECTIVE: We estimate the proportion of patients with crotaline snake envenomation who are treated with Crotalidae polyvalent immune Fab (ovine) antivenom and who develop medically significant late bleeding. METHODS: We performed a systematic review of all published cohort studies of North American crotaline snake envenomation patients treated with Fab antivenom. We searched PubMed, Ovid MEDLINE, and EMBASE from January 1, 1997, to April 30, 2012. Data were extracted by 2 trained researchers. Late bleeding was defined as bleeding that began or recurred after initial control of the envenomation syndrome. Medically significant late bleeding was defined a priori as late bleeding treated with RBC transfusion, vasoactive drug infusion, surgery, or rehospitalization or associated with a hemoglobin decrease of greater than or equal to 3 g/dL, hematocrit decrease of greater than or equal to 8%, disability, or death. Summary incidence and 95% confidence intervals (CIs) were calculated with a random-effects Poisson regression model. RESULTS: Nineteen unique cohort studies were identified. Four studies collected data prospectively, and in 9 studies, patients were followed actively after hospital discharge. A total of 1,017 subjects were enrolled in these cohort studies. Late bleeding was reported in 9 subjects (0.9%; 95% CI 0.4% to 2.2%), of whom 5 subjects (0.5%; 95% CI 0.1% to 1.7%) had medically significant late bleeding. Three patients received RBC transfusion; no deaths or permanent sequelae were reported. Estimates of risk may be affected by underreporting. CONCLUSION: Medically significant late bleeding appears to be uncommon in snakebite victims treated with Fab antivenom.
STUDY OBJECTIVE: We estimate the proportion of patients with crotaline snake envenomation who are treated with Crotalidae polyvalent immune Fab (ovine) antivenom and who develop medically significant late bleeding. METHODS: We performed a systematic review of all published cohort studies of North American crotaline snake envenomationpatients treated with Fab antivenom. We searched PubMed, Ovid MEDLINE, and EMBASE from January 1, 1997, to April 30, 2012. Data were extracted by 2 trained researchers. Late bleeding was defined as bleeding that began or recurred after initial control of the envenomation syndrome. Medically significant late bleeding was defined a priori as late bleeding treated with RBC transfusion, vasoactive drug infusion, surgery, or rehospitalization or associated with a hemoglobin decrease of greater than or equal to 3 g/dL, hematocrit decrease of greater than or equal to 8%, disability, or death. Summary incidence and 95% confidence intervals (CIs) were calculated with a random-effects Poisson regression model. RESULTS: Nineteen unique cohort studies were identified. Four studies collected data prospectively, and in 9 studies, patients were followed actively after hospital discharge. A total of 1,017 subjects were enrolled in these cohort studies. Late bleeding was reported in 9 subjects (0.9%; 95% CI 0.4% to 2.2%), of whom 5 subjects (0.5%; 95% CI 0.1% to 1.7%) had medically significant late bleeding. Three patients received RBC transfusion; no deaths or permanent sequelae were reported. Estimates of risk may be affected by underreporting. CONCLUSION: Medically significant late bleeding appears to be uncommon in snakebite victims treated with Fab antivenom.
Authors: Eileen E Henderson; Cynthia K Stadler; Robert H Poppenga; Javier Asin Ros; Francisco A Uzal Journal: J Vet Diagn Invest Date: 2021-09-11 Impact factor: 1.569
Authors: Anne-Michelle Ruha; Kurt C Kleinschmidt; Spencer Greene; Meghan B Spyres; Jeffrey Brent; Paul Wax; Angela Padilla-Jones; Sharan Campleman Journal: J Med Toxicol Date: 2017-10-03
Authors: Sean P Bush; Anne-Michelle Ruha; Steven A Seifert; David L Morgan; Brandon J Lewis; Thomas C Arnold; Richard F Clark; William J Meggs; Eric A Toschlog; Stephen W Borron; Gary R Figge; Dawn R Sollee; Farshad M Shirazi; Robert Wolk; Ives de Chazal; Dan Quan; Walter García-Ubbelohde; Alejandro Alagón; Richard D Gerkin; Leslie V Boyer Journal: Clin Toxicol (Phila) Date: 2014-10-31 Impact factor: 4.467
Authors: Shelby S Szteiter; Ilse N Diego; Jonathan Ortegon; Eliana M Salinas; Abcde Cirilo; Armando Reyes; Oscar Sanchez; Montamas Suntravat; Emelyn Salazar; Elda E Sánchez; Jacob A Galan Journal: Toxins (Basel) Date: 2021-03-31 Impact factor: 4.546
Authors: Nicholas Kevin Willard; Emelyn Salazar; Fabiola Alejandra Oyervides; Cierra Siobhrie Wiebe; Jack Sutton Ocheltree; Mario Cortez; Ricardo Pedro Perez; Harry Markowitz; Anton Iliuk; Elda Eliza Sanchez; Montamas Suntravat; Jacob Anthony Galan Journal: Toxins (Basel) Date: 2021-09-15 Impact factor: 4.546